FluoroPharma Medical, Inc., a biopharmaceutical company, is engaged in the discovery and development of proprietary PET imaging products used to evaluate cardiac disease at the cellular and molecular levels. The company is focused on advancing two products undergoing clinical trials for the assessment of acute and chronic forms of coronary artery disease. Other active programs include the development of agents that could potentially be used for imaging specific cancers. For more information, visit the company’s website at www.fluoropharma.com.